# Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim

> **NCT01439321** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 280 (actual)

## Conditions studied

- Immune Thrombocytopenic Purpura

## Interventions

- **BIOLOGICAL:** Eltrombopag
- **BIOLOGICAL:** Romiplostim

## Key facts

- **NCT ID:** NCT01439321
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2012-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439321, "Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01439321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*